ANIP
ANI Pharmaceuticals Inc

1,125
Mkt Cap
$1.91B
Volume
141,017.00
52W High
$99.50
52W Low
$52.50
PE Ratio
52.04
ANIP Fundamentals
Price
$84.56
Prev Close
$84.85
Open
$85.11
50D MA
$89.93
Beta
0.75
Avg. Volume
331,935.61
EPS (Annual)
-$1.04
P/B
3.77
Rev/Employee
$684,923.08
Loading...
Loading...
News
all
press releases
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?
ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Here is how ANI Pharmaceuticals (ANIP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
Zacks·3d ago
News Placeholder
Dynamic Technology Lab Private Ltd Makes New Investment in ANI Pharmaceuticals, Inc. $ANIP
Dynamic Technology Lab Private Ltd purchased a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the second quarter, according to the company in its most recent...
MarketBeat·3d ago
News Placeholder
Universal Beteiligungs und Servicegesellschaft mbH Has $4.22 Million Holdings in ANI Pharmaceuticals, Inc. $ANIP
Universal Beteiligungs und Servicegesellschaft mbH increased its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 14.0% during the 2nd quarter, according to its most recent filing...
MarketBeat·7d ago
News Placeholder
Envestnet Asset Management Inc. Raises Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP
Envestnet Asset Management Inc. grew its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 59.9% in the second quarter, according to its most recent disclosure with the Securities...
MarketBeat·7d ago
News Placeholder
ANI Pharmaceuticals, Inc. $ANIP Shares Acquired by Intech Investment Management LLC
Intech Investment Management LLC boosted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 134.7% in the second quarter, according to the company in its most recent Form 13F...
MarketBeat·8d ago
News Placeholder
Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth
ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.
Zacks·10d ago
News Placeholder
Why 2025 is a Dynamic and Transformative Year for Collegium
COLL's bold buybacks, board refresh and expanding ADHD push highlight a year of strategic moves and rising momentum.
Zacks·10d ago
News Placeholder
ANI (ANIP) Loses 15% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for ANI (ANIP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·12d ago
News Placeholder
Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) Director Sells 8,643 Shares of Stock
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) Director Patrick Walsh sold 8,643 shares of the firm's stock in a transaction dated Thursday, November 13th. The stock was sold at an average...
MarketBeat·13d ago

Latest ANIP News

View

Advertisement|Remove ads.

Advertisement|Remove ads.